TriangleLm-GUCY2C vaccine (NCT07417488)
Lm-GUCY2C vaccine trial for Colorectal Cancer and Small Bowel Adenocarcinoma (NCT07417488). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for advanced colorectal cancer and small bowel adenocarcinoma that has progressed on standard therapies, in adults.
The idea: a two step vaccine, called prime boost. First comes one injection into the muscle. Four weeks later, two doses by vein of a second vaccine, Lm GUCY2C, made from recombinant Listeria, at one of three rising dose levels.
This single center phase 1 trial plans 18 patients. The main measure is the rate of dose limiting toxicities, to find the recommended dose. At Thomas Jefferson University in Philadelphia, Babar Bashir leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.